ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
Meeting Date | Thursday, November 7, 2024 |
Meetings | One-on-one and small group meetings: November 7, 2024 |
Management | Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.72 |
| Daily Change: | -0.84 -12.80 |
| Daily Volume: | 4,097,947 |
| Market Cap: | US$659.340M |
October 14, 2025 September 08, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
